Characteristics of lymphocyte subpopulations in the peripheral blood and lymph nodes of patients with ovarian cancer

More and more data suggest that ovarian cancer (OC) is an immunogenic tumor. Clinical trials dealing with immunotherapy based on activated natural killer (NK) cells and dendritic cells (DC) are under way. Mononuclear cells (MNCs) from both peripheral blood and lymph nodes (LN) are proposed to be used as a source of immunity effectors. This paper characterizes peripheral blood and LN effector cells in patients with OC. The peripheral blood displayed T cell subpopulations: T helper cells, cytotoxic T lymphocytes, and NK cells. LN showed virtually no expression of NK cell antigens, but exhibited the expression of markers of DC and T regulatory cells at the same time. The cytotoxic activity of MNCs against autologous tumor cells was higher than that against the K562 cell line. OC tissue samples were observed to contain low tumor-infiltrating lymphocyte counts.

1. Zhang L., Conejo-Garcia J.R., Katsaros D. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203–13.

2. Chu C.S., Kim S.H., June C.H., Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008;8(2):243–57.

3. Kandalaft L.E., Powell D.J. Jr., Singh N., Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol 2011;29(7):925–33.

4. Адоптивная клеточная терапия: клинические исследования. В кн.: Биологические методы лечения онкологических заболеваний. Под ред. В.Т. ДеВита, С. Хеллман, С.А. Розенберг. Пер. с англ. М.: Медицина, 2002. С. 504–22.

5. Hontscha C., Borck Y., Zhou H. et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137(2):305–10.

6. Моисеенко В.М. Вакцинотерапия при меланоме кожи. Рос онкол журн 2005;3:52–6.

7. Sabado R.L., Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2010;2(1):37–56.

8. Valteau-Couanet D., Leboulaire C., Maincent K. et al. Dendritic cells for NK/ LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002;100(7):2554–61.

9. Kimura H., Iizasa T., Ishikawa A. et al. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor draining lymph nodes in primary lung cancer patients. Anticancer Res 2008;28(2В):1229–38.

10. Шубина И.Ж., Титов К.С., Лебединская О.В. и др. Сравнительная характеристика лимфокин-активированных киллеров, генерированных из различных источников. Рос биотер журн 2006;3:43–50.

11. Сепиашвили Р.И., Балмасова И.П. Физиология естественных киллеров. М.: Медицина–Здоровье, 2005. C. 456.

12. Vuylsteke R.J., van Leeuwen P.A., Meijer S. et al. Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 2002;161(1):19–26.

13. Santin A.D. Lymph node metastases: the importance of the microenvironment. Cancer 2000;88(1):175–9.

14. De Vries I.J., Krooshoop D.J., Scharenborg N.M. et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63(1):12–7.

15. Tanaka H., Tanaka J., Kjaergaard J., Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002;25(3):207–17.

16. Ishigami S., Natsugoe S., Hokita S. et al. Intranodal antitumor immunocyte infiltration in node-negativegastric cancers. Clin Cancer Res 2000;6(7):2611–7.

17. Dong H., Strome S.E., Salomao D.R. et al. Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8): 793–800.

18. Jiang J., Xu N., Wu C. et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006;26(3B): 2237–42.

19. Hui D., Qiang L., Jian W. et al. A randomized controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009;41(1):36–41.

20. Weng D.S., Zhou J., Zhou Q.M. et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008;31(1):63–71.

21. Титов К.С., Демидов Л.В., Киселевский М.В. и др. Внутриплевральная иммунотерапия метастатических плевритов у больных раком молочной железы. Опухоли женской репродуктивной системы 2009;(3–4):29–33.

22. Nguyen L.T., Yen P.H., Nie J. et al. Expansion and сharacterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS One 2010;5(11):е13940.

23. Brunner A., Hinterholzer S., Riss P. et al. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol 2012;124(1):105–11.

24. Wu R., Forget M.A., Chacon J. et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012;18(2):160–75.